Drug Target Review2024-10-02T12:00:52
Sygnature Discovery has created a platform named SCANME, which can scale up human disease modelling to develop novel therapeutics.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2026-07-01T06:30:00
Sponsored by BPS Bioscience, Dr Veronique Baron
2026-06-04T07:05:00
Author Graham Craig
2024-01-09T09:30:19
Sponsored by Sartorius
2026-07-21T09:36:00
Contributor Jayson Uffens, Drug Target Review
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2026-03-25T15:00:00
Sponsored by Yokogawa
Site powered by Webvision Cloud